On Sunday, the University of North Carolina at Chapel Hill and GSK, a world known pharmaceutical and healthcare company, announced the creation of a HIV Cure center. Both also jointly own a new company whose main aim would be to come up with cure for HIV/AIDS.

The centre, located on the UNC campus, would be focusing on discovering a cure the disease. On the other hand, the company, Qura Therapeutics, will take care of the business aspect of the partnership. Among the things that will be handled by the company include intellectual property, commercialization, manufacturing and governance.

Top talent would be recruited for the task accomplishment. UNC-Chapel Hill Chancellor Carol L. Folt said, “This first of its kind, joint-ownership model is a novel approach toward finding a cure, and we hope it serves as an invitation to the world's best researchers and scientists. Today, Carolina's best are taking another major step in the global fight against HIV/AIDS”.

GSK CEO Sir Andrew Witty affirmed that like UNC, their company also has the legacy of HIV research success. In the 1980s, the company developed the world’s first medicine for HIV patients. GSK enjoys the topmost position in the market owing to ViiV Healthcare. And, they continue to take on challenges to meet the requirements of people, affirmed he.

The partnership is prove of the successes that they have achieved in the past and continue to do so now as well. Witty stated that they have the needed confidence and are inspired by the fact that they have right resources and research teams. All things clubbed together would result into a cure for HIV.

As a part of partnership, UNC and GSK will try latest scientific methods to come up with a cure of HIV. The latest approaches will help to find out the hidden virus that remains in people with HIV despite the fact they have taken drug therapy.

In the partnership, GSK will invest $4 million per year for five year. The university will provide lab space on its medical campus.